GlaxoSmithKline PLC Directorate Change (0525H)
20 Marzo 2020 - 3:00PM
UK Regulatory
TIDMGSK
RNS Number : 0525H
GlaxoSmithKline PLC
20 March 2020
Issued: 20 March 2020, London UK
GSK appoints Charles Bancroft to the Board as a Non-Executive
Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Charles
Bancroft will join the Board of the Company as a Non-Executive
Director on 1 May 2020.
Charlie has recently retired from a successful career at Bristol
Myers Squibb (BMS) where he held a number of leadership roles in
commercial, strategy and finance. Beginning his career at BMS in
1984, he held positions of increasing responsibility within the
finance organisation and had commercial operational responsibility
for Latin America, Middle East, Africa, Canada, Japan and several
Pacific Rim countries. He was appointed Chief Financial Officer in
2010, Chief Financial Officer and Executive Vice President, Global
Business Operations in 2016 and Executive Vice President and Head
of Integration and Strategy & Business Development in 2019.
Charlie successfully steered BMS through a period of strategic
transformation, including the recent $74bn acquisition of
Celgene.
Charlie served as a member of the Board of Colgate-Palmolive
Company from 2017 until March 2020.
On joining the Board Charlie will become a member of the Audit
& Risk Committee. He will succeed Judy Lewent as Chair of this
Committee following approval of GSK's 2020 Annual Report in Q1 of
2021.
Commenting on the appointment, Sir Jonathan Symonds, Chairman of
GSK said: "I am delighted Charlie is joining the GSK Board and has
agreed to succeed Judy in 2021 as Chair of our Audit & Risk
Committee. He brings a wealth of financial and management
experience in global biopharma which will be invaluable to the
Board in the coming years as it oversees the delivery of GSK's
strategy, including the separation of the Group and the creation of
two outstanding new companies."
Notes
1. The appointment of Charles Bancroft was made by the Board on the
recommendation of the Nominations Committee.
2. The Board determined that Mr Bancroft is an independent Non-Executive
Director on appointment in accordance with the UK Corporate Governance
Code (the Code). He has also been designated as having recent and
relevant financial experience for the purposes of the Code and
as an audit committee financial expert as defined in rules promulgated
under the Sarbanes-Oxley Act of 2002.
3. He will receive the standard basic fee for a Non-Executive Director
of GBP95,000 per annum and when he succeeds Ms Lewent as Chair
of the Audit & Risk Committee, he will receive the supplemental
fee of GBP80,000 per annum. He will be required to invest at least
25% of his fees in GSK shares that should be held until he retires
from the Board.
4. Membership of other Committees will be determined in due course.
5. Mr Bancroft does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
6. There are no additional details to disclose in respect of Mr Bancroft's
appointment under Listing Rule 9.6.13R.
7. From 1 May 2020 the Board of GSK will comprise:
Sir Jonathan Symonds Non-Executive Chairman
Emma Walmsley Chief Executive Officer
Iain Mackay Chief Financial Officer
Dr Hal Barron Chief Scientific Officer and President, R&D
Vindi Banga Senior Independent Non-Executive Director
Charles Bancroft Independent Non-Executive Director
Dr Vivienne Cox Independent Non-Executive Director
Lynn Elsenhans Independent Non-Executive Director
Dr Jesse Goodman Independent Non-Executive Director
Dr Laurie Glimcher Independent Non-Executive Director
Judy Lewent Independent Non-Executive Director
Urs Rohner Independent Non-Executive Director
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
GSK enquiries:
UK Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Mary Hinks-Edwards +44 (0) 20 8047 (London)
5502
US Media enquiries: Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor Sarah Elton-Farr +44 (0) 208 (London)
enquiries: 047 5194
Danielle Smith +44 (0) 20 8047 (London)
7562
James Dodwell +44 (0) 20 8047 (London)
2406
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Principal risks and uncertainties' in the company's Annual Report
on Form 20-F for 2019.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKZGZFFGNGGZM
(END) Dow Jones Newswires
March 20, 2020 10:00 ET (14:00 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024